Startups & VC

Life Biosciences Series B $80 million (April 8)

ER-100 epigenetic ophthalmology Phase 1 lift-off. Aging and vision-regeneration track secures core funding.

Primary sources · 1
Fierce Biotech
← View the full 2026-04-10 (Friday) issue
What you're reading now arrives in your inbox daily at 21:00 UTC.

Get today's brief every day at 21:00 UTC

7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.

Past issues →